Ascendis Pharma A/S

Ascendis Pharma A/S

257.93
USD
+7.76
(+3.10%)
13.31EPS
19.50P/E
17.52BMarket Cap
Nov 11Next Earn

Ascendis Pharma A/S Documents

Q4 FY2025 · Presentation

YUVIWEL® (navepegritide) FDA Approval · 23 pages

Read Ascendis Pharma A/S's results firsthand

Preview the first 2 pages of this presentation
Create a free account to start reading

Full documents are included with Professional

Q4 FY2025 documents